Rhabdomyolysis-Induced Renal FailureMYORHEINNCT07853677
Impact of Extrarenal Myoglobin Clearance on Renal Recovery in Patients With Severe Rhabdomyolysis
An observational study of Rhabdomyolysis-Induced Renal Failure, run by University Hospital, Strasbourg, France at 1 site in France.
Trial summary
Severe rhabdomyolysis is a common medical emergency that can lead to acute kidney injury (AKI), sometimes requiring extracorporeal renal replacement therapy (ECRT). Myoglobin plays a major role among the molecules involved in nephrotoxicity. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Rhabdomyolysis-Induced Renal Failure
- How many people
- 100 participants
- Where
- 1 siteFrance
- Study dates
- 8 Apr 2025to 31 Dec 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: Adult patient (≥18 years) with confirmed diagnosis of severe rhabdomyolysis associated with acute kidney injury, with or without renal replacement therapy.
Who may be able to join
- Adult patient (≥18 years).
- Patient is hospitalized in the nephrology or medical intensive care units of the Strasbourg University Hospitals (NHC or Hautepierre) between 2015 and 2024.
- Confirmed diagnosis of severe rhabdomyolysis associated with acute kidney injury, with or without renal replacement therapy.
- Patient has not objected to the reuse of their medical data.
Who cannot join
- Patient has objected to the reuse of their data.
- Incomplete medical file preventing the complete analysis of the data necessary for the study.
- Subject under guardianship, curatorship, or legal protection.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
Service de Néphrologie Dialyse Transplantation - CHU de Strasbourg - France
Strasbourg, 67091
Nans FLORENS, MD, 33 3 69 55 13 25, nans.florens@chru-strasbourg.fr
Nans FLORENS, MD
About this study
Official title: Retrospective Evaluation of the Impact of Extrarenal Myoglobin Clearance on Renal Recovery in Patients With Severe Rhabdomyolysis
Severe rhabdomyolysis is a common medical emergency that can lead to acute kidney injury (AKI), sometimes requiring extracorporeal renal replacement therapy (ECRT). Myoglobin plays a major role among the molecules involved in nephrotoxicity. While ECRT techniques are commonly used in this situation, their actual effectiveness in eliminating myoglobin and improving renal function remains poorly established. In particular, mid-cut-off membranes, developed to better remove intermediate molecular weight molecules, could improve renal prognosis. This study aims to evaluate, using retrospective clinical data, the impact of these techniques on renal recovery.
- Conditions
- Rhabdomyolysis-Induced Renal Failure
- Keywords
- Rhabdomyolysis, Renal Failure, Extracorporeal Myoglobin
- Medical subject headings
- Rhabdomyolysis, Renal Insufficiency
What is being measured
The primary outcome is the main question the study is designed to answer.
Total duration of dependence on extrarenal purification (ERP) (in days)
Total duration of dependence on ERC (in days), defined as the number of days between initiation and discontinuation of any form of dialysis.
Measured: up to 15 month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Oct 2026
- Study start8 Apr 2025
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Rhabdomyolysis-Induced Renal FailureStudies of the same condition, open and under way.
- More trials run by University Hospital, Strasbourg, FranceThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Strasbourg, France
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07853677
- Sponsor's protocol ID
- 9619
- Acronym
- MYORHEIN
- Status last verified
- Dec 2025
- First submitted
- 31 Dec 2025
- Last updated
- 2 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Retrospective Evaluation of the Impact of Extrarenal Myoglobin Clearance on Renal Recovery in Patients With Severe Rhabdomyolysis
- ClinicalTrials.gov ID
- NCT07853677
- Acronym / sponsor ID
- MYORHEIN / 9619
- Conditions
- Rhabdomyolysis-Induced Renal Failure
- Keywords
- Rhabdomyolysis, Renal Failure, Extracorporeal Myoglobin
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- University Hospital, Strasbourg, FranceUniversity, hospital or other
- Study start
- 8 Apr 2025 (actual)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 2 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Severe rhabdomyolysis is a common medical emergency that can lead to acute kidney injury (AKI), sometimes requiring extracorporeal renal replacement therapy (ECRT). Myoglobin plays a major role among the molecules involved in nephrotoxicity. While ECRT techniques are commonly used in this situation, their actual effectiveness in eliminating myoglobin and improving renal function remains poorly established. In particular, mid-cut-off membranes, developed to better remove intermediate molecular weight molecules, could improve renal prognosis. This study aims to evaluate, using retrospective clinical data, the impact of these techniques on renal recovery.
Study design
- Observational model
- Case only
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- Adult patient (≥18 years) with confirmed diagnosis of severe rhabdomyolysis associated with acute kidney injury, with or without renal replacement therapy.
Key inclusion criteria (4 listed)
- Adult patient (≥18 years).
- Patient is hospitalized in the nephrology or medical intensive care units of the Strasbourg University Hospitals (NHC or Hautepierre) between 2015 and 2024.
- Confirmed diagnosis of severe rhabdomyolysis associated with acute kidney injury, with or without renal replacement therapy.
- Patient has not objected to the reuse of their medical data.
Key exclusion criteria (3 listed)
- Patient has objected to the reuse of their data.
- Incomplete medical file preventing the complete analysis of the data necessary for the study.
- Subject under guardianship, curatorship, or legal protection.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Total duration of dependence on extrarenal purification (ERP) (in days)
Time frame: up to 15 month
Total duration of dependence on ERC (in days), defined as the number of days between initiation and discontinuation of any form of dialysis.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Oct 2026.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Rhabdomyolysis-Induced Renal Failure, run by University Hospital, Strasbourg, France at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 2 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Nans FLORENS, MD (33 3 69 55 13 25, nans.florens@chru-strasbourg.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Total duration of dependence on extrarenal purification (ERP) (in days) (time frame: up to 15 month). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Oct 2026.